WuXi Biologics (2269)

Hong Kong
105.00
+0.20(+0.19%)
  • Volume:
    9,211,885
  • Bid/Ask:
    105.00/105.10
  • Day's Range:
    103.00 - 106.40

2269 Overview

Prev. Close
104.8
Day's Range
103 - 106.4
Revenue
6.71B
Open
106
52 wk Range
74.7 - 128.6
EPS
0.48
Volume
9,211,885
Market Cap
442.52B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
21,747,652
P/E Ratio
220.11
Beta
1.47
1-Year Change
0%
Shares Outstanding
4,214,440,871
Next Earnings Date
Nov 30, 2
What is your sentiment on WuXi Biologics?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuySellStrong BuyBuy
SummaryStrong BuyStrong BuyNeutralStrong BuyStrong Buy

WuXi Biologics Company Profile

WuXi Biologics Company Profile

Employees
5694
Market
Hong Kong

WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing of biologics services. The Company's technology platforms include WuXiBody TM bispecific antibody technology platform and antibody drug conjugates (ADC) technology platform. It has brought in several new projects into its pipeline. The Company has a vaccine manufacturing facility and produces vaccines for customers to supply the global market. The Company conducts its businesses within the China market and to overseas markets, such as North America, Europe and other markets.

Read More
  • JPM Hikes WUXI BIO TP to $130; Rated ***Overweight***
    0
    • Nomura Chops WUXI BIO TP to $116.8, Rated ***Buy***
      0
      • Definitely will back to 120 by end of this year. Company future is very good. Next factory to be setup to increase capacity expansion is ongoing till 2023. Stay tune for the extraordinary earning in the coning years. Surely a high growth positive cashflow company in China 👍🏻
        0
        • Daiwa: WUXI BIO ( Share Correction Overdone Entails Bottom-fish Odds, Restated ***Buy***
          0
          • This is oversold. Buy the dip
            0
            • C Suisse: WUXI BIO Share Price Likely Bumpy on Vir COVID Neutrializing Antibody Clinical Trial Failure
              0
              • WUXI BIO Mulls Placing Shrs at Nearly 7% Discount, Net Proceeds Expected to Top $13.1B***jm
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.